FORMULATION AND IN-VITRO EVALUATION OF LACIDIPINE ORAL DISINTEGRATING TABLETS: ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE

Pharmaceutical Science-Pharmaceutics

Authors

  • KAMBHAM VENKATESWARLU Assistant Professor, Department of Pharmaceutics, Oil Technological & Pharmaceutical Research nstitute, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu, Andhra Pradesh, India.
  • K.B.CHANDRASEKHAR Proferssor & Director, Department of Chemistry, Oil Technological & Pharmaceutical Research Institute, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu, Andhra Pradesh, India.

Keywords:

Lacidipine, Solid dispersions, Oral disintegrating tablets, Phase solubility studies, Solubility enhancement.

Abstract

The aim of present study was to develop the Lacidipine oral disintegrating tablets (LCDP ODTs), thereby enhancing the solubility and dissolution rate. Solubility was enhanced by solid dispersion technology using hydrophilic carriers like Hydroxy Propyl   Methyl Cellulose Acetate Succinate (HPMCAS), β-Cyclodextrin (BCD), Polyethylene Glycol 6000 (PEG 6000) and it was confirmed by phase solubility studies. LCDP ODTs were prepared by using super disintegrants like Croscarmellose Sodium (CCS), Crospovidone (CP), Sodium Starch  glycolate  (SSG).  Evaluation  parameters  were  complied  with  the  official  limits.  From  the  in-vitro dissolution studies, it was observed that the formulation F9 consists of CP showed maximum drug release within short period of time.

 

Published

2022-06-17

How to Cite

KAMBHAM VENKATESWARLU, & K.B.CHANDRASEKHAR. (2022). FORMULATION AND IN-VITRO EVALUATION OF LACIDIPINE ORAL DISINTEGRATING TABLETS: ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE: Pharmaceutical Science-Pharmaceutics. International Journal of Life Science and Pharma Research, 6(2), 16–26. Retrieved from https://www.ijlpr.com/index.php/journal/article/view/372

Issue

Volume 6 Issue 2, April - June 2016

Section

Research Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.